Condition: Breast Cancer, Early Breast Cancer · Sponsor: AstraZeneca
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
AstraZeneca Breast Cancer Study Locator Service · 1-877-400-4655 · az-bcsl@careboxhealth.com
Always discuss trial participation with your own doctor first.
| Research Site | Birmingham, Alabama, United States | Active Not Recruiting |
| Research Site | Dothan, Alabama, United States | Active Not Recruiting |
| Research Site | Anchorage, Alaska, United States | Active Not Recruiting |
| Research Site | Chandler, Arizona, United States | Active Not Recruiting |
| Research Site | Hot Springs, Arkansas, United States | Active Not Recruiting |
| Research Site | Anaheim, California, United States | Active Not Recruiting |
| Research Site | Beverly Hills, California, United States | Active Not Recruiting |
| Research Site | Concord, California, United States | Active Not Recruiting |
| Research Site | Corona, California, United States | Active Not Recruiting |
| Research Site | Fountain Valley, California, United States | Active Not Recruiting |
| Research Site | Greenbrae, California, United States | Active Not Recruiting |
| Research Site | Los Alamitos, California, United States | Active Not Recruiting |
+ 697 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05774951